Products Atazanavir + Ritonavir
Atazanavir + Ritonavir Approved Completed ⚡ Active Interest: 43/100
Nov 30, 2012 → Feb 20, 2017
About Atazanavir + Ritonavir Atazanavir + Ritonavir is a approved stage product being developed by Bristol Myers Squibb for HIV, Pediatric. The current trial status is completed. This product is registered under clinical trial identifier NCT01691794. Target conditions include HIV, Pediatric.
What happened to similar drugs? 2 of 18 similar drugs in HIV, Pediatric were approved
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT01691794 Approved Completed Nov 30, 2012 Feb 20, 2017 HIV, Pediatric NCT00337467 Phase 3 Completed Jun 1, 2006 May 1, 2009 Human Immunodeficiency Virus (HIV) Infections
Product Company Stage Hype Score Ramucirumab Eli Lilly Phase 1 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine Sun Pharmaceutical Phase 1 Perampanel Oral Suspension + Perampanel Tablet Eisai Phase 2 Eribulin Mesylate Eisai Phase 1 Decitabine + Decitabine Eisai Phase 2 Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily Sumitomo Pharma Phase 1 Remimazolam Tosilate for injection + Propofol Injection Jiangsu Hengrui Medicine Phase 2/3 Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid AstraZeneca Phase 2/3 candsartan cilexetil AstraZeneca Phase 3 Durvalumab / Tremelimumab Combination Therapy AstraZeneca Phase 1/2 Rotavirus Vaccine Merck Pre-clinical basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids Novartis Phase 3 VAL489 + VAL489 matching placebo Novartis Phase 3 LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696 Novartis Phase 2/3 Everolimus Novartis Phase 2 Corticosteroids + Cyclosporine + mycophenolate mofetil Roche Phase 2 Entecavir + Lamivudine + Pegylated Interferon Alfa-2A Roche Phase 3 Blinatumomab for Injection Amgen Phase 1 Etanercept Amgen Phase 3